 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This indicator may be signaling that DNTH's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Dianthus Therapeutics (DNTH, $13.09) entered Downtrend as Momentum indicator drops below 0 level on Oct 03, 2023

This is a Bearish indicator signaling DNTH's price could decline from here. Traders may explore shorting the stock or put options...

Dianthus Therapeutics (DNTH, $13.28) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 2, 2023

Related Stocks: DNTH, AXSM, IMGN, COGT, NUVL, ELVN...

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

Dianthus Therapeutics, Inc. (NASDAQ:DNTH  Get Free Report) insider Simrat Randhawa bought 2,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, September...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Insider Buys $26,400.00 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH  Get Free Report) Director Fairmount Funds Management Llc acquired 14,887 shares of Dianthus Therapeutics stock in a transaction that occurred on...

Insider Buying: Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Acquires $161,523.95 in Stock

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. Its lead antibody, DNTH103, is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology, enabling less frequent and more convenient self-administered subcutaneous injections to improve the lives of patients. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Watchers	1,298
52-Wk Low	$5.14
52-Wk High	$28.96

Market Cap	$49.67M
Volume (M)	26,148.00
52-Wk High	$28.96
52-Wk Low	$5.14

DNTH Dianthus Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals